Cadila Healthcare rises after USFDA nod for Isosorbide Dinitrate tablets, Desonide Cream

Cadila Healthcare rose 1.95% to 253.9 after the company said it received final approvals from the US drug regulator for Isosorbide Dinitrate tablets and Desonide Cream.

The stock has risen 13.02% in six trading sessions from its previous closing low of Rs 224.65 on 13 November 2019.

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Isosorbide Dinitrate tablets USP (US RLD Isordil tablet) in the strengths of 5 mg, 10 mg, 20 mg, 30 mg and 40 mg. The drug is used to prevent attacks of chest pain (angina). It dilates (widens) blood vessels, making it easier for blood to flow through them and easier for the heart to pump. It will be manufactured at the group's formulations manufacturing facility at Baddi.

The group also received the final approval for Desonide Cream (US RLD Desonide Cream), 0.05%. The drug is a mild corticosteroid, used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash) to reduce swelling, itching and redness that can occur in these types of conditions. It will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

The group now has 278 approvals and has so far filed over 330 Abbreviated New Drug Application (ANDAs) since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.

Powered by Capital Market - Live News